Home > Insider Trading > Filing (0001479290-24-000066)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1479290	Revance Therapeutics Inc.	RVNC	Pharmaceutical Preparations (2834)	770551645

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1678984	Tobin Schilke	C/O Revance Therapeutics, Inc. 1222 Demonbreun Street, 20Th Floor Nashville TN 37203	Cfo	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2024-03-15	3,822	$5.31	202,027	No	4	F	Direct
Common Stock	Disposition	2024-03-18	9,361	$5.04	192,666	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	F	Direct
No	4	S	Direct

Footnotes

Represents the number of shares withheld by and surrendered to the Issuer on March 15, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of a restricted stock award (the "RSA") for 7,540 shares. The RSA vested in three equal annual installments from March 15, 2021.
Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based restricted stock units ("PSUs") granted on January 31, 2023, which vest over a three-year period based on the achievement of revenue goals. This sale is mandated by the Issuer's sell to cover agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.